Radiopharm Theranostics Ltd 6-K, filed Oct 20, 2026
Radiopharm Theranostics Ltd (RADX)
About this 6-K
Radiopharm Theranostics Ltd filed this 6-K on October 20, 2026.
Radiopharm Theranostics Limited reported listed-option cancellations across four director notices and issued 140,028,000 unquoted employee incentive options. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on October 20, 2026 titled:
“Change of Director's Interest Notices x 4”
“Notification regarding unquoted securities - RAD”
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.
1
EXHIBITS
| Exhibit
Number |
Description | |
| 99.1 | Change of Director's Interest Notices x 4 | |
| 99.2 | Notification regarding unquoted securities - RAD |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
| Date: October 20, 2026 | By: | /s/ Amritha Sushil |
| Amritha Sushil | ||
| Company Secretary | ||
3
Exhibit 99.1
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001. Amended 01/01/11
| Name of Entity: | Radiopharm Theranostics Limited (ASX: RAD) |
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director: | Bruce Goodwin |
| Date of Last Notice: | 22 September 2026 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Indirect | ||||
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Sundial Management Pty Limited of which of which Mr Goodwin is a Director and Shareholder. | ||||
| Date of change | 16 October 2026 | ||||
| No. of securities held prior to change | Shares | Options | |||
| Indirect | 2,777,778 | 2,777,778 | |||
| Class | Listed Options | ||||
| Number acquired | Nil |
||||
| Number disposed | 1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018 | ||||
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
Nil | ||||
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| No. of securities held after change | Shares | Options | |||
| Indirect | 2,777,778 | 1,666,667 | |||
Nature of change Example:
|
Cancellation of Listed options | ||||
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001. Amended 01/01/11
Name of Entity: |
Radiopharm Theranostics Limited (ASX: RAD) |
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: |
Ian Turner |
| Date of Last Notice: | 22 September 2026 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct and indirect | ||||
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Superannuation fund | ||||
| Date of change | 16 October 2026 | ||||
| No. of securities held prior to change | Shares | Options | |||
| Direct | 3,752,817 | 23,179,148 | |||
| Indirect | 9,010,253 | 1,625,978 | |||
| Total | 12,763,070 | 24,805,126 | |||
| Class | Listed Options | ||||
| Number acquired | Nil |
||||
| Number disposed | 1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018 | ||||
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
Nil | ||||
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| No. of securities held after change | Shares | Options | |||
| Direct | 3,752,817 | 22,068,037 | |||
| Indirect | 9,010,253 | 1,625,978 | |||
| Total | 12,763,070 | 23,694,015 | |||
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
Cancellation of Listed options | ||||
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
Name
of registered holder |
N/A |
| Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 3 |
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001. Amended 01/01/11
| Name of Entity: | Radiopharm Theranostics Limited (ASX: RAD) |
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director: | Paul Hopper |
| Date of Last Notice: | 22 September 2026 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||||
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
N/A | ||||
| Date of change | 16 October 2026 | ||||
| No. of securities held prior to change | Shares | Options | |||
| Direct | 53,900,000 | 26,142,000 | |||
| Indirect | 96,599,206 | 11,795,296 | |||
| Total | 150,499,206 | 37,937,296 | |||
| Class | Listed Options | ||||
| Number acquired | Nil | ||||
| Number disposed | 1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018 |
||||
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
Nil | ||||
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| No. of securities held after change | Shares | Options | |||
| Direct | 53,900,000 | 26,142,000 | |||
| Indirect | 96,599,206 | 10,684,185 | |||
| Total | 150,499,206 | 36,826,185 | |||
Nature of change Example:
|
Cancellation of Listed options. | ||||
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 3 |
| Appendix 3Y |
| Change of Director’s Interest Notice |
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001. Amended 01/01/11
| Name of Entity: | Radiopharm Theranostics Limited (ASX: RAD) |
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director: | Riccardo Canevari |
| Date of Last Notice: | 1 October 2026 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Direct | ||||
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
N/A | ||||
| Date of change | 16 October 2026 | ||||
| No. of securities held prior to change | Shares | Options | |||
| Direct | 23,918,875 | 163,301,188 | |||
| Indirect | 2,650,000 | - | |||
| Total | 26,568,875 | 163,301,188 | |||
| Class | Listed Options |
||||
| Number acquired | Nil | ||||
| Number disposed | 1,555,556 Listed Options, EXP 31 Jul 29, EX $0.018 | ||||
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
Nil |
||||
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 1 |
| Appendix 3Y |
| Change of Director’s Interest Notice |
| No. of securities held after change | Shares | Options | |||
| Direct | 23,918,875 | 161,745,632 | |||
| Indirect | 2,650,000 | - | |||
| Total | 26,568,875 | 161,745,632 | |||
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
Cancellation of Listed options. | ||||
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| 01/01/2011 | Appendix 3Y Page 3 |
Exhibit 99.2
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Announcement Summary
Entity name
RADIOPHARM THERANOSTICS LIMITED
Date of this announcement
Tuesday October 20, 2026
The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Total number of +securities to be issued/transferred
| ASX +security code | Security description | Total number of + securities to be issued/transferred |
Issue date | |||
| RADAN | OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 140,028,000 | 19/10/2026 |
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 1 / 6 |
| |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Part 1 - Entity and announcement details
1.1 Name of entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
| 1.2 Registered number type | Registration number |
| ACN | 647877889 |
1.3 ASX issuer code
RAD
1.4 The announcement is
New announcement
1.5 Date of this announcement
20/10/2026
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 2 / 6 |
| |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code (“existing class”)
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 3 / 6 |
| |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities in an existing class issued under an +employee incentive scheme
ASX +security code and description
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
Date the +securities the subject of this notification were issued
19/10/2026
Will these +securities rank equally in all respects from their issue date with the existing issued
+securities in that class
Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate?
Yes
Provide details of the KMP or +associates being issued +securities.
| Name of KMP | Name of registered holder | Number of +securities | |||
| Dimitris Voliotis | Dimitris Voliotis | 30,887,000 |
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
| Refer to page 33 of the 2025 Notice of Annual General Meeting for the Material terms of the Omnibus Incentive Plan: http s://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03011824-2A1630827&v=undefined |
Any other information the entity wishes to provide about the +securities the subject of this notification
| n/a |
Issue details
Number of +securities
140,028,000
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 4 / 6 |
| |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| ASX +security code and description | Total number of +securities on issue | |||
| RADO : OPTION EXPIRING 30-NOV-2026 | 79,352,040 | |||
| RAD : ORDINARY FULLY PAID | 4,710,882,790 | |||
| RADOC : OPTION EXPIRING 31-JUL-2029 | 982,172,830 | |||
| RADOB : OPTION EXPIRING 31-OCT-2027 | 1,179,266,658 | |||
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
| ASX +security code and description | Total
number of | |||
| RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60 | 1,666,500 | |||
| RADAAB : WARRANT EXPIRING 31-JUL-2029 EX USD3.79 | 1,281,646 | |||
| RADAAC : WARRANT EXPIRING 31-JUL-2029 EX USD3.95 | 64,082 | |||
| RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 503,207,525 | |||
| RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17 | 12,425,675 | |||
| RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | 8,666,678 | |||
| RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60 | 5,066,672 | |||
| RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60 | 740,000 | |||
| RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09 | 8,955,224 | |||
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 5 / 6 |
| |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 6 / 6 |